Feb 7 - Dr. Kathryn Wagner
The work of Dr. Wagner and her colleagues has brought new hope to people with muscular dystrophy. Dr. Wagner has shown that myostatin inhibition has improved the condition of mice with muscular dystrophy and that loss of myostatin in humans is associated with increased muscle mass.
The development of a treatment for Duchenne and Facioscapulohumeral muscular dystrophy through Myostatin inhibition with novel pharmacologic agents is a current goal of Dr. Wagner’s research. Her work at Vita Therapeutics has also been deemed revolutionary, with the company using induced pluripotent stem cell technology to engineer specific cell types designed to replace defective ones in patients.
#febRAREuary #GNEmyopathy #rarediseaseday #rarewomen #womeninfocus